Mr. Glenn Saldanha Honoured With ‘Swiss Ambassador’s Award for Exceptional Innovation’

Mr. Glenn Saldanha Honoured With ‘Swiss Ambassador’s Award for Exceptional Innovation’ Mr. Glenn Saldanha Becomes the Third Recipient of This Prestigious Award After Mr. Ratan Tata, Chairman, Tata Group in 2011 and Mr. Yash Chopra in 2010 Swiss Ambassador Dr. Linus von Castelmur honoured Mr. Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Limited with ‘Swiss Ambassador’s Award for Exceptional Innovation’ for his outstanding innovation-driven leadership on November 29, 2012 at an event organised at the Embassy of Switzerland in New Delhi. Acknowledging Mr. Glenn Saldanha’s contributions in the area of innovation Ambassador Dr. Linus von Castelmur said, “Innovation has Read More


Glenmark aims at Rs 5k cr revenue during FY13, focus on US

Glenmark aims at Rs 5k cr revenue during FY13, focus on US Glenmark Pharmaceuticals on Thursday said it is aiming for up to 30 percent growth in revenues this fiscal to touch Rs 5,000 crore, with the US and Latin America expected to be primary contributors. Glenmark Pharmaceuticals on Thursday said it is aiming for up to 30 percent growth in revenues this fiscal to touch Rs 5,000 crore, with the US and Latin America expected to be primary contributors. “With a 25-to-30 per cent growth, we expect to achieve Rs 5,000 crore in revenues by the end of this Read More


Glenn Saldanha – 11 Debutantes on the India rich list

Glenn Saldanha – 11 Debutantes on the India rich list There are 11 entrepreneurs debuting on the India Rich List this year. Bruce Upbin/Forbes India There are 11 entrepreneurs debuting on the India Rich List this year No. 61 Glenn Saldanha USD 1.03 billion Source: Pharmaceuticals Age: 41. Married, 2 children Residence: Mumbai Takes the spot of his father, Gracias, founder of Glenmark Pharmaceuticals, who died in July. A pharmacist with an MBA from New York University, he has been running the firm since 2000. He masterminded the USD 756-million (revenues) firm’s entry into drug discovery in 2001; it has seven new Read More


May not see 35% growth in H1 sustaining in H2: Glenmark

May not see 35% growth in H1 sustaining in H2: Glenmark Glenn Saldanha, MD & CEO, Glenmark said the pharma major is growth at the rate of 30% in the Indian market and is confident of maintaining margins ahead. Glenn Saldanha, MD & CEO, Glenmark said the pharma major is growth at the rate of 30% in the Indian market and is confident of maintaining margins ahead. The drug maker clocked a net profit of Rs 156 crore for the second quarter ended September 30 compared with Rs 56 crore registered in the corresponding quarter last year. But the company’s Read More


ˆ Back To Top